Scalable Synthesis of a Prostaglandin EP4 Receptor Antagonist
摘要:
The evolution of scalable, economically viable synthetic approaches to the potent and selective prostaglandin EP4 antagonist 1 is presented. The chromatography-free synthesis of multikilogram quantities of 1 using a seven-step sequence (six in the longest linear sequence) is described. This approach has been further modified in an effort to identify a long-term manufacturing route. Our final synthesis involves no step requiring cryogenic (< - 25 degrees C) conditions; comprises a total of four steps, only three of which are in the longest linear synthesis; and features the use of two consecutive iron-catalyzed Friedel-Crafts substitutions.
[EN] HETEROBICYCLIC COMPOUNDS AS EP4 ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROBICYCLIQUES EN TANT QU'ANTAGONISTES EP4
申请人:SHENZHEN IONOVA LIFE SCIENCE CO LTD
公开号:WO2019152982A1
公开(公告)日:2019-08-08
The present invention relates to novel EP4 receptor antagonist compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, which can be useful for treating cancer or inflammatory diseases.
本发明涉及由式(I)表示的新型EP4受体拮抗剂化合物或其药用盐,可用于治疗癌症或炎症性疾病。
THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS
申请人:Blouin Marc
公开号:US20090247596A1
公开(公告)日:2009-10-01
The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II).
PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES
申请人:DAVIES Ian
公开号:US20100204487A1
公开(公告)日:2010-08-12
The invention encompasses a process for making a thiophene carboxamide derivative, which is an EP4 antagonist useful for treating pain and inflammation.